Interleukin 17 Antibody from MyBioSource.com

The primary function of the body defense mechanism/immune system is to protect the organism from invading pathogens. In this regard a very effective and dynamic cellular network has evolved that comprise of innate and adaptive immunity. Most components of innate immunity are present before the onset of infection and constitute cellular and molecular components that recognize classes of molecules peculiar to pathogens. In contrast, adaptive immunity responds to the challenge with a high degree of specificity as well as the remarkable property of memory. Although adaptive immune responses are the most effective to clear invading pathogens (1, 2), innate immune responses should be precedent of activation of adaptive immune cells (2). In other words, adaptive immune responses can not arise without help of innate immune responses. Antigen presenting cells (APCs) are key initiators of immune responses. During infection various cytochines are released and via activation of various TLR receptor family, they synthesized various interleukins. IL17 gene was mapped at a single site on mouse chromosome 1A and human chromosome 2q31 (2). Pro inflammatory cytokine, IL-17 (IL-17A or CTLA-8) plays a central role in inflammation and autoimmunity. The iIL17, like other cytokines is produce by activation of T cell receptor through CD3 cross linking (1). IL-17 is a crucial effector cytokine, whose production is specifically triggered by IL-23, and it has been shown to be an essential inflammatory mediator in other autoimmune diseases and inflammatory conditions. In human the co-stimulation of T cells thru CD28 several costimulatory molecules (ICOS, 4-1BB, CD40L) mildly enhance the IL17 expression where as IL23 profoundly enhance the CD3 induced IL17 expression. The IL-17 expression is also sensitive to cyclosporin-A and MAPK inhibitors, suggesting the involvement of the calcineurin/NFAT and MAPK signaling pathways. The predicted 155-amino acids sequence contains an N-terminal signal peptide and exhibits 72% amino acid identity with HVS13, an open reading frame from a T-lymphotropic Herpesvirus saimiri, and 63% with murine CTLA8 (3). Based on hydropathy plot has 2 transmembrane domains (TMD) at N and C-terminal end of the protein. The anti-IL17 antibodies were made against an epitope that lies near the extracytoplasmic domain on IL17 protien. The antibodies to IL17 were affinity purified on immobilized affinity based chromatography and characterized using recombinant IL17 western blot positive control sample. The IL17 antibodies fdo not cross react with other pro-inflammatory or anti-inflammatory interleukins, or with other proteins. MyBioSource has also produced antibodies to IL17 receptor and other cytokines and their receptor, for a complete listing please visit www.mybiosource.com. MyBioSource will also provide western blot positive control for IL17 and other interluekins in ready-to-use buffer for SDS-PAGE and Western blotting experiment. Limited quantities of antigenic blocking peptides are also available (please inquire about